IN8bio posts Q1 2026 loss, updates GBM data

IN8bio, Inc. reported first quarter 2026 results and highlighted progress in its γδ T cell pipeline.

Rhea-AI Filing Summary

IN8bio, Inc. reported first quarter 2026 results and highlighted progress in its γδ T cell pipeline. Net loss was $5.1 million, or $0.26 per share, compared with a $5.6 million loss a year earlier, as R&D expenses fell modestly to $2.6 million.

Updated clinical data in newly diagnosed glioblastoma showed median progression-free survival of 13.0 months for repeat-dose patients versus 6.6 months for standard-of-care, and median overall survival of 17.2+ months versus 13.2 months, with no dose-limiting toxicities or cytokine release syndrome reported.

Stockholders approved the Amended and Restated 2026 Equity Incentive Plan, adding 2,920,000 shares available for awards, extending the annual share increase through 2037, and setting a 20,000,000-share cap for incentive stock options. Director nominees and the independent auditor were also ratified by wide margins.

Insights

Biotech fundamentals analyst

Early GBM data and TCE progress are encouraging, while losses remain controlled.

IN8bio is a clinical-stage company, so pipeline progress is central. Repeat-dose γδ T cell therapy in newly diagnosed glioblastoma showed median progression-free survival of 13.0 months versus 6.6 months for standard-of-care, with median overall survival of 17.2+ months versus 13.2.

The absence of dose-limiting toxicities, cytokine release syndrome or neurotoxicities in this dataset supports continued development but does not establish efficacy. The INB-600 γδ T cell engager platform, including INB-619 moving into IND-enabling studies with initial animal data expected in 2026, broadens potential indications.

Financially, net loss of $5.1 million in Q1 2026 and cash of $21.9 million as of March 31, 2026 indicate measured spending. The expanded 2026 Equity Incentive Plan, adding 2,920,000 shares and allowing annual increases through 2037, increases potential future equity-based compensation over time.

8-K Event Classification

4 items: 2.02, 5.02, 5.07, 9.01

4 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Cash balance: $21.9 million Net loss: $5.1 million R&D expenses: $2.6 million +5 more

8 metrics

Cash balance $21.9 million Cash as of March 31, 2026

Net loss $5.1 million Net loss for quarter ended March 31, 2026

R&D expenses $2.6 million Research and development, Q1 2026

G&A expenses $2.7 million General and administrative, Q1 2026

mPFS improvement 13.0 vs 6.6 months Median PFS repeat-dose GBM vs standard-of-care

Median overall survival 17.2+ vs 13.2 months Repeat-dose GBM vs standard-of-care as of Dec 31, 2025

Equity plan share increase 2,920,000 shares Additional shares under 2026 Equity Incentive Plan

ISO share cap 20,000,000 shares Maximum ISOs under 2026 Equity Incentive Plan

Key Terms

γδ T cell engagers, median progression-free survival, median overall survival, incentive stock options, +2 more

6 terms

γδ T cell engagers medical

"a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer"

median progression-free survival medical

"Median progression-free survival (mPFS) for repeat dose patients was 13.0 months versus 6.6 months"

Median progression-free survival is the length of time at which half of patients in a clinical study have not experienced disease worsening or progression. Think of it like the moment in a race when 50% of runners have not yet crossed a trouble line—it shows how long a therapy can delay disease activity for a typical patient. Investors use it as a straightforward signal of a drug’s effectiveness that can influence regulatory approval, market demand, and revenue potential.

median overall survival medical

"Median overall survival (mOS) in repeat dose patients is still climbing, currently at 17.2+ months"

Median overall survival is the middle point of how long patients live after starting treatment, meaning half live longer and half live shorter. It helps doctors understand how effective a treatment is and gives patients an idea of what to expect about their future.

incentive stock options financial

"maximum number of shares that may be subject to awards granted in the form of ISOs; • extend the outside date that ISOs may be granted"

Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.

Annual Share Increase financial

"extend the period of time during which shares of common stock will be added to the 2026 Plan on an annual basis through 2037 (the "Annual Share Increase")"

cylokine release syndrome (CRS) medical

"minimal CRS-associated cytokine release (IL-6, TNF-α), reinforcing the platform’s differentiation and therapeutic potential"

Earnings Snapshot

Net loss: $5.1 million

Q1 2026

Net loss $5.1 million

R&D expenses $2.6 million

G&A expenses $2.7 million

Cash balance $21.9 million

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did IN8bio (INAB) perform financially in the first quarter of 2026?

IN8bio reported a net loss of $5.1 million, or $0.26 per share, for the quarter ended March 31, 2026. Total operating expenses were $5.3 million, slightly lower than a year earlier, reflecting reduced research and development spending while general and administrative costs stayed stable.

What key clinical results did IN8bio (INAB) report in glioblastoma?

IN8bio reported updated data in newly diagnosed glioblastoma showing median progression-free survival of 13.0 months for repeat-dose patients versus 6.6 months for standard-of-care. Median overall survival reached 17.2+ months versus 13.2 months, with no dose-limiting toxicities or cytokine release syndrome observed.

What is IN8bio’s cash position and balance sheet as of March 31, 2026?

As of March 31, 2026, IN8bio held $21.9 million in cash, compared with $27.1 million at December 31, 2025. Total assets were $26.3 million and total liabilities were $3.5 million, resulting in stockholders’ equity of approximately $22.8 million.

What changes were approved in IN8bio’s 2026 Equity Incentive Plan?

Stockholders approved the Amended and Restated 2026 Equity Incentive Plan, increasing shares available for issuance by 2,920,000. The plan extends annual share increases through 2037, sets a 20,000,000-share limit for incentive stock options, and updates provisions tied to pre-funded warrant settlements.

How did IN8bio (INAB) stockholders vote on the 2026 Equity Incentive Plan?

Approval of the 2026 Equity Incentive Plan received 5,064,465 votes for, 1,106,779.83 against, and 14,060 abstentions, with 1,776,813.17 broker non-votes. This outcome shows stockholder support for expanding and extending the company’s equity-based compensation framework.

What progress did IN8bio report on its INB-619 γδ T cell engager program?

IN8bio presented preclinical data for INB-619, a CD19-targeting γδ T cell engager, showing complete B cell depletion, robust γδ T cell expansion, and minimal cytokine release. The program is moving into IND-enabling studies, with initial animal data expected during 2026 according to company guidance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 04:31 PM Learn about SEC filing dates

0001740279false00017402792026-05-072026-05-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 07, 2026

IN8bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39692	82-5462585
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
350 5th Avenue, Suite 5330
New York, New York				10118
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 646 600-6438

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		INAB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 7, 2026, IN8bio, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

As described in Item 5.07 below, on May 7, 2026, at the Company’s 2026 annual meeting of stockholders (the "Annual Meeting"), the Company’s stockholders approved the Company’s Amended and Restated 2026 Equity Incentive Plan (the "2026 Plan"), which is the successor to the Company’s Amended and Restated 2023 Equity Incentive Plan. The 2026 Plan had previously been adopted by the Company’s Board of Directors (the "Board"), subject to stockholder approval. In addition to changing the plan’s name, the 2026 Plan includes changes to:

•increase the number of shares available for issuance under the 2026 Plan by 2,920,000 shares of common stock, which also includes a corresponding increase in the number of shares of common stock available for issuance under the 2026 Plan pursuant to the exercise of “incentive stock options” as defined in Section 422 of the Internal Revenue Code ("ISOs");

•extend the period of time during which shares of common stock will be added to the 2026 Plan on an annual basis through 2037 (the "Annual Share Increase");

•establish 20,000,000 shares as the maximum number of shares that may be subject to awards granted in the form of ISOs;

•extend the outside date that ISOs may be granted under the 2026 Plan to the tenth anniversary of the earlier of March 26, 2026, which is the date the 2026 Plan was adopted by the Board, or the date the Company’s stockholders approved the 2026 Plan; and

•revise the Annual Share Increase to provide that common stock issuable upon settlement of any of outstanding pre-funded warrants be added to the total number of shares of common stock that are issued and outstanding as of each December 31st to which the formula will be applied for purposes of calculating the annual increase under the Annual Share Increase.

A summary of the terms of the 2026 Plan is set forth in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on March 26, 2026 (the "Proxy Statement"), under the heading "Proposal 3: Approval of the Amended and Restated 2026 Equity Incentive Plan," and is incorporated by reference herein. This summary does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the 2026 Plan, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held the Annual Meeting on May 7, 2026. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Proxy Statement.

Proposal No. 1: Election of two nominees to serve as Class II directors, each to serve until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. All nominees were elected. The votes were cast as follows:

Name		Votes For		Votes Withheld		Broker Non-Votes
Peter Brandt		5,206,187.67		979,117.17		1,776,813.17
Corinne Epperly		6,143,941.67		41,363.17		1,776,813.17

Proposal No. 2: Ratification of the selection of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The selection was ratified. The votes were cast as follows:

		Votes For		Votes Against		Abstained
Ratification of selection of CohnReznick LLP		7,898,219.83		8,644.17		55,254

Proposal No. 3: Approval of the 2026 Plan. The 2026 Plan was approved. The votes were case as follows:

		Votes For		Votes Against		Abstained		Broker Non-Votes
Approval of the 2026 Plan		5,064,465		1,106,779.83		14,060		1,776,813.17

Item 9.01 Financial Statements and Exhibits.

d) Exhibits.

Exhibit No.		Description
10.1		Amended and Restated 2026 Equity Incentive Plan.
10.2		Forms of Option Grant Notice and Option Agreement under the Amended and Restated 2026 Equity Incentive Plan.
99.1		Press Release, dated May 7, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		IN8bio, Inc.
Date:	May 7, 2026	By:	/s/ Patrick McCall
			Patrick McCall
			Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)

Exhibit 99.1

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

•Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026

•Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026

•Hosting R&D Day on May 21, 2026 in New York City

NEW YORK, May 7, 2026 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and autoimmune diseases, today reported financial results and business highlights for the first quarter ended March 31, 2026.

“In the first quarter of 2026, we continued to advance our next-generation TCE platform and clinical programs,” said William Ho, Chief Executive Officer and co-founder of IN8bio. “Our encouraging GBM data positions us to engage the FDA on potential regulatory pathways forward, and we expect to deliver meaningful preclinical, regulatory and clinical milestones across our pipeline this year. As industry interest in novel TCEs accelerates, our next-generation platform is designed to address the key challenges in TCE development. We believe IN8bio is well positioned to create meaningful value for patients and shareholders in 2026 and beyond. We look forward to sharing further updates across our programs at our upcoming R&D Day in New York City on May 21, 2026.”

Key Highlights

Advancing Next-Generation Gamma-Delta T Cell Engager Platform (INB-619)

•Continued to advance our internally developed INB-600 platform of novel γδ T cell engagers, designed to potently eliminate targets such as CD19, potentially reduce toxicities such as cytokine release syndrome (CRS) and widen the therapeutic window over traditional CD3-targeting engagers.

•Presented encouraging preclinical data for INB-619, a CD19-targeting γδ T cell engager for oncology and autoimmune diseases. The data showed complete B cell depletion, robust γδ T cell expansion, and minimal CRS-associated cytokine release (IL-6, TNF-α), reinforcing the platform’s differentiation and therapeutic potential.

•Progressing INB-619 into IND-enabling studies, with initial animal data expected in 2026.

Presented Clinical Data Demonstrating Durable Survival Improvements in Newly Diagnosed Glioblastoma

In January 2026, IN8bio reported updated data as of December 31, 2025, from its Phase 1 (INB-200) and Phase 2 (INB-400) clinical trials evaluating DeltEx drug resistant immunotherapy (DRI) γδ T cells in patients with newly diagnosed GBM. The data included a concurrent standard-of-care (SOC) control group enrolled at the same time and clinical sites as treated patients.

•Median progression-free survival (mPFS) for repeat dose patients was 13.0 months versus 6.6 months for SOC patients (+97% improvement).

•Median overall survival (mOS) in repeat dose patients is still climbing, currently at 17.2+ months as of December 31, 2025, surpassing the 13.2-months for the SOC control arm.

•Several patients remained progression-free beyond two years, including one grade 4, IDH-mutant glioma patient who remains progression-free with no additional therapy for more than 4.5 years.

•No dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), neurotoxicity (ICANS), tumor inflammation-associated neurotoxicity (TIAN) or other unexpected severe adverse events were reported.

•Updated mOS results to be presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting (Abstract 2077, Poster 442) on June 1, from 1:30 - 4:30 p.m. CDT.

IN8bio Research & Development Day 2026

•IN8bio will host its R&D Day on May 21, 2026 (9:00 - 11:30 a.m. EDT), in New York City.

•The event will feature presentations on the Company’s γδ TCE platform targeting oncology and autoimmune diseases.

•The Company will also provide updates on its clinical program in GBM, including a clinical perspective from renowned neuro-oncologist Dr. David Reardon, Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.

•Register Online: https://investors.in8bio.com/news-events/events-presentations.

Upcoming Conferences & Anticipated Milestones

International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting (Dublin, Ireland)

•Title: Unraveling Complexity: The Impact, Interactions and Outcomes of a γδ T Cell Therapy in Glioblastoma

Poster Details: 1253
Date/Time: May 7, 2026, 18:00 to 19:30 GMT (1:00 - 2:30 p.m. EDT)

•Title: Lean Infrastructure for CGT Early-Stage Companies: Leveraging Integrated Digital Platforms to Achieve Sustainable Operation Efficiency and Scalable Compliance

Poster Details: 801
Date/Time: May 7, 2026, 18:00 to 19:30 GMT (1:00 - 2:30 p.m. EDT)

American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting (Boston, MA)

•Title: Challenging the Glioblastoma Status Quo: Could γδ T Cells Shift the Balance?
Abstract: 328

Date and Time: May 14, 2026, 11:00 - 11:15 a.m. EDT

Anticipated Milestones

•Guidance from the FDA on potential accelerated regulatory pathways for GBM program in 2H26.

•Publication of Phase 1 INB-200 clinical data in newly diagnosed GBM patients in a peer-reviewed journal.

•Additional GBM clinical updates, including updated mOS data at ASCO 2026.

•Initial TCE preclinical animal data and additional IND-enabling data for INB-619 in 2H26.

•Completion of INB-100 patient dosing and presentation of long-term follow-up results at a medical meeting in late 2026.

First Quarter 2026 Financial Highlights

•Cash position: As of March 31, 2026, the Company had cash of $21.9 million, compared with $11.9 million, for the comparable prior year period.

•Research and Development (R&D) expenses: R&D expenses were $2.6 million for the three months ended March 31, 2026, compared with $3.0 million for the comparable prior year period. These amounts include non-cash items

such as stock-based compensation (SBC) and depreciation. The decrease primarily reflects lower clinical trial activity in the INB-400 program.

•General and administrative (G&A) expenses: G&A expenses were $2.7 million for the three months ended March 31, 2026, compared with $2.7 million for the comparable prior year period. These amounts include non-cash items such as stock-based compensation (SBC) and depreciation.

•Net loss: The Company reported a net loss of $5.1 million, or $0.26 per basic and diluted common share, for the three months ended March 31, 2026, compared with a net loss of $5.6 million, or $2.16 per basic and diluted common share, for the comparable prior year period.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell

engager (TCE) product candidates to address unmet medical needs. γδ T cells are

a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Forward Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of IN8bio’s product candidates; the potential of repeat-dose γδ T cell therapy to meaningfully improve outcomes in newly diagnosed glioblastoma; the potential of IN8bio’s INB-600 platform to improve durability and safety compared with traditional CD3-targeting engagers; IN8bio’s ability to achieve anticipated milestones, including receipt of guidance from the FDA on regulatory pathways, expected presentations and data readouts from its preclinical studies and clinical trials, patient dosing timelines and advancement of clinical development plans; the milestone-driven closing of the private placement and the use of proceeds from the private placement; IN8bio’s cash runway; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or

events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations; IN8bio’s ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its DeltEx platform and TCE program; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause IN8bio’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section entitled “Risk Factors” in IN8bio’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 12, 2026, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Investors and Corporate Contact:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

IN8BIO, INC.

BALANCE SHEETS

(In thousands, except share and per share data)

		March 31,
		2026				December 31,
		(unaudited)				2025
Assets						(Note 2)
Current assets
Cash		$	21,941			$	27,092
Prepaid expenses and other current assets			721				788
Total Current Assets			22,662				27,880
Non-current assets
Property and equipment, net			1,622				1,858
Restricted cash			220				220
Right-of-use assets - finance leases			188				296
Right-of-use assets - operating leases			1,444				1,882
Other non-current assets			129				146
Total Non-Current Assets			3,603				4,402
Total Assets		$	26,265			$	32,282
Liabilities and Stockholders' Equity
Liabilities
Current liabilities
Accounts payable		$	449			$	309
Accrued expenses and other current liabilities			681				1,633
Short-term finance lease liability			189				295
Short-term operating lease liability			839				924
Total Current Liabilities			2,158				3,161
Long-term operating lease liability			1,326				1,563
Total Non-Current Liabilities			1,326				1,563
Total Liabilities			3,484				4,724
Stockholders' Equity
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; no shares issued and outstanding			—				—
Common stock, par value $0.0001 per share; 490,000,000 shares authorized at March 31, 2026 and December 31, 2025; 9,847,089 and 9,766,132 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively			10				10
Additional paid-in capital			168,957				168,644
Accumulated deficit			(146,186	)			(141,096	)
Total Stockholders' Equity			22,781				27,558
Total Liabilities and Stockholders' Equity		$	26,265			$	32,282

IN8BIO, INC.

STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

		Three Months Ended March 31,
		2026				2025
Operating expenses:
Research and development		$	2,613			$	2,972
General and administrative			2,653				2,688
Total operating expenses			5,266				5,660
Interest income			176				110
Loss from operations			(5,090	)			(5,550	)
Net loss		$	(5,090	)		$	(5,550	)
Net loss per share – basic and diluted		$	(0.26	)		$	(2.16	)
Weighted-average number of shares used in computing net loss per common share, basic and diluted			19,467,114				2,575,325

Investors & Company Contacts:

IN8bio, Inc.

Patrick McCall

646.933.5603

pfmccall@IN8bio.com

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744

kimberly.ha@kkhadvisors.com

# # #

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 211.1 KB

Agreements & Contracts

• EX-10.1 EX-10.1 314.2 KB
• EX-10.2 EX-10.2 67.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.4 KB